INVO Fertility, Inc. (NAYA)
- Previous Close
1.9200 - Open
1.9000 - Bid 1.8500 x 400
- Ask 1.9900 x 100
- Day's Range
1.8584 - 2.0500 - 52 Week Range
1.3800 - 17.0400 - Volume
44,512 - Avg. Volume
55,282 - Market Cap (intraday)
1.305M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-12.1200 - Earnings Date Apr 24, 2025 - Apr 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as solid and pediatric tumors; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases. The company also offers INVOcell, a a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
nayabiosciences.comRecent News: NAYA
View More
Performance Overview: NAYA
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NAYA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NAYA
View MoreValuation Measures
Market Cap
1.13M
Enterprise Value
13.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.08
Price/Book (mrq)
--
Enterprise Value/Revenue
2.19
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.86M
Diluted EPS (ttm)
-12.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--